A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer

Completed · Phase 1

Conditions studied: Pancreatic Cancer

In brief

Gemcitabine is considered one of the standard drugs for advanced pancreatic cancer and is approved by the FDA to treat it. Cabozantinib is a new drug that has demonstrated effectiveness against pancreatic cancer in laboratory experiments, especially when given with gemcitabine. Initial studies with cabozantinib in pancreatic cancer have shown some activity against the disease. The purpose of this study is to determine the safest and highest dose of cabozantinib that can be given together with standard doses of gemcitabine in patients with pancreatic cancer. This study will determine the safety and tolerability of this two drug combination.

Key facts

Study ID

NCT01663272

Run by

University of Michigan Rogel Cancer Center

People needed

12

Starts

2012-07-01

Expected to finish

2017-03-01

Last updated by the study team

2018-09-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• pathologically confirmed pancreatic carcinoma.
• locally advanced unresectable disease, metastatic disease, or recurrent disease following surgical therapy.
• ≥ 18 years old.
• Life expectancy of greater than 12 weeks.
• ECOG performance status ≤1 (Karnofsky ≥70%) (See Appendix A).
• adequate organ and marrow function as follows:
• capable of understanding and complying with the protocol requirements and has signed the informed consent document.
• use medically accepted barrier methods of contraception
• women of childbearing potential must have a negative pregnancy test at screening.

You may not qualify if…

• neuroendocrine tumors of the pancreas.
• more than 1 prior systemic treatment regimen for pancreatic cancer. may have received prior neoadjuvant or adjuvant therapy, including gemcitabine, provided 6 months have elapsed from completion of that treatment and the start of study therapy.
• Previous gemcitabine therapy for advanced pancreatic cancer. Patients who have had chemotherapy within 4 weeks, nitrosoureas/mitomycin C within 6 weeks, or monoclonal antibody within 6 weeks prior to planned initiation of study treatment.
• prior treatment with a small molecule kinase inhibitor or a hormonal therapy within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment.
• have received an investigational agent within 28 days of the first dose of study treatment or 5 half-lives of the compound or active metabolite, whichever is longer.
• have received radiation therapy within 14 days of study treatment.
• have not recovered from toxicity due to all prior therapies (i.e., return to pretherapy baseline or to CTCAE Grade 0 or 1) except alopecia and non-clinically significant AEs.
• known brain metastases.

Where it is running

• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.